Suppliers and packagers for generic pharmaceutical drug: ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Zevra Therap	APADAZ	acetaminophen; benzhydrocodone hydrochloride	TABLET;ORAL	208653	NDA	Zevra Therapeutics, Inc.	70040-0145-1	100 TABLET in 1 BOTTLE, PLASTIC (70040-0145-1)	2018-02-23
Zevra Therap	APADAZ	acetaminophen; benzhydrocodone hydrochloride	TABLET;ORAL	208653	NDA	Zevra Therapeutics, Inc.	70040-0167-1	100 TABLET in 1 BOTTLE, PLASTIC (70040-0167-1)	2018-02-23
Zevra Therap	APADAZ	acetaminophen; benzhydrocodone hydrochloride	TABLET;ORAL	208653	NDA	Zevra Therapeutics, Inc.	70040-0189-1	100 TABLET in 1 BOTTLE, PLASTIC (70040-0189-1)	2018-02-23

Acetaminophen and Benzhydrocodone Hydrochloride: Supplier Landscape Analysis

Last updated: February 19, 2026

This report analyzes the global supplier landscape for acetaminophen and benzhydrocodone hydrochloride, focusing on key manufacturers, production capacities, and regulatory considerations. The data presented aids in strategic sourcing and risk mitigation for pharmaceutical development and manufacturing.

Acetaminophen Manufacturing and Supply

Acetaminophen, a widely used analgesic and antipyretic, has a mature and fragmented supply chain. Production is concentrated in regions with established chemical manufacturing infrastructure and favorable cost structures.

Key Manufacturers and Production Regions

Global acetaminophen production is dominated by manufacturers in China and India, leveraging economies of scale and lower operational costs. Western manufacturers also maintain significant production, often focusing on higher-purity grades or serving domestic markets.

• China: Holds the largest share of global acetaminophen production. Major suppliers include:
  • Anqiu Luyuan Pharmaceutical Co., Ltd.
  • Hebei Jiheng Pharmaceutical Co., Ltd.
  • Jiangsu Zhongbang Pharmaceutical Co., Ltd.
• India: A significant producer, with companies like:
  • Divi's Laboratories Limited
  • Granules India Ltd.
  • Sarthak Pharmaceuticals Pvt. Ltd.
• Europe: Several European companies produce acetaminophen, often catering to specialized markets or adhering to stringent regional quality standards:
  • DSM (Netherlands)
  • Delpharm (France)
  • IOL Chemicals and Pharmaceuticals Limited (though primarily Indian, has a global presence)
• United States: Domestic production exists but is generally at a smaller scale compared to Asian manufacturers.

Production Capacity and Scale

Estimates suggest that global acetaminophen production capacity exceeds 200,000 metric tons annually. This capacity is distributed across numerous facilities, with large-scale plants in China and India capable of producing tens of thousands of metric tons each. The fragmented nature of the market means that no single supplier controls a dominant market share.

Regulatory Landscape and Quality Standards

Acetaminophen Active Pharmaceutical Ingredient (API) must comply with pharmacopoeial standards, including the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). Manufacturers are subject to Good Manufacturing Practices (GMP) inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Supplier qualification processes typically involve audits of manufacturing sites and review of regulatory filings, such as Drug Master Files (DMFs).

Supply Chain Risks and Mitigation

Potential risks in the acetaminophen supply chain include:

• Geopolitical instability: Disruptions in major producing regions can impact global availability.
• Raw material price fluctuations: The cost of key precursors like phenol and nitric acid can affect acetaminophen pricing.
• Quality control issues: Batch-to-batch consistency and adherence to stringent purity standards are critical.
• Environmental regulations: Increasingly strict environmental controls in manufacturing regions can lead to production slowdowns or increased costs.

Mitigation strategies involve diversifying the supplier base across different geographic regions, establishing long-term contracts, and maintaining sufficient inventory levels. Dual sourcing for critical raw materials is also advisable.

Benzhydrocodone Hydrochloride Manufacturing and Supply

Benzhydrocodone hydrochloride is a Schedule II controlled substance in the United States, primarily used as an opioid analgesic. Its supply chain is significantly more restricted and regulated than that of acetaminophen due to its controlled substance status and more complex synthesis.

Key Manufacturers and Production

The manufacturing of benzhydrocodone hydrochloride is highly concentrated among a few specialized pharmaceutical companies that possess the necessary licenses and expertise to handle controlled substances. Production is primarily concentrated in the United States and Europe, where regulatory oversight is robust.

• United States: Manufacturers with DEA (Drug Enforcement Administration) registration are essential. Key players include:
  • Mallinckrodt Pharmaceuticals (historically a major producer)
  • Hikma Pharmaceuticals (through its acquisition of Roxane Laboratories)
  • Specialty API manufacturers with controlled substance licenses.
• Europe: A limited number of European manufacturers may also produce benzhydrocodone hydrochloride, subject to national and EU regulations for controlled substances.

The production volume of benzhydrocodone hydrochloride is significantly lower than that of acetaminophen, reflecting its more specialized therapeutic use and stricter prescribing guidelines.

Production Capacity and Quotas

As a Schedule II controlled substance, the production of benzhydrocodone hydrochloride is subject to annual aggregate production quotas set by the DEA in the U.S. and equivalent bodies in other countries. These quotas limit the total amount of the substance that can be legally manufactured, imported, and processed in a given year. This regulatory mechanism directly controls supply and is a critical factor in market availability. The total global production capacity is difficult to quantify precisely due to the proprietary nature of these operations and the quota system, but it is considerably smaller than that of widely produced generic APIs.

Regulatory Landscape and Controlled Substance Handling

The manufacture, distribution, and handling of benzhydrocodone hydrochloride are governed by stringent national and international regulations.

• DEA (U.S. Drug Enforcement Administration): Requires manufacturers, distributors, and researchers to register and adhere to strict security, record-keeping, and reporting requirements. Production quotas are a key aspect of DEA oversight.
• International Narcotics Control Board (INCB): Oversees international drug control treaties and provides estimates for annual import and export quotas.
• FDA (U.S. Food and Drug Administration) / EMA (European Medicines Agency): Regulate the quality, safety, and efficacy of the finished drug product, requiring compliance with GMP.

Suppliers must demonstrate robust security measures to prevent diversion and maintain meticulous documentation of all transactions. Audits by regulatory agencies are frequent and rigorous.

Supply Chain Risks and Mitigation

The supply chain for benzhydrocodone hydrochloride presents unique and significant risks:

• Strict Regulatory Control: Changes in quotas, manufacturing licenses, or diversion control measures can severely impact supply.
• Limited Supplier Base: The small number of authorized manufacturers creates a high degree of reliance on existing suppliers.
• Security Risks: The potential for diversion and illicit trade necessitates extremely high security protocols, increasing operational costs.
• Dependence on Precursors: The synthesis of benzhydrocodone hydrochloride involves controlled precursors, which are also subject to regulation and supply chain scrutiny.
• DEA Quota Allocations: Delays or reductions in quota allocations can lead to drug shortages.

Mitigation strategies for benzhydrocodone hydrochloride involve:

• Early Engagement with Regulators: Proactive communication with agencies like the DEA regarding anticipated production needs.
• Robust Supplier Qualification: Thorough vetting of potential suppliers' compliance history, security infrastructure, and regulatory standing.
• Long-Term Contracts with Strict Safeguards: Securing supply through contracts that include provisions for regulatory compliance and security.
• Contingency Planning: Developing alternative sourcing strategies, though limited by the controlled nature of the substance.
• Inventory Management: Maintaining appropriate inventory levels, balancing the risk of obsolescence against the need for uninterrupted supply.

Comparative Analysis: Acetaminophen vs. Benzhydrocodone Hydrochloride

The supply chains for acetaminophen and benzhydrocodone hydrochloride differ fundamentally due to their chemical properties, therapeutic uses, and regulatory classifications.

Feature	Acetaminophen	Benzhydrocodone Hydrochloride
Therapeutic Class	Analgesic, Antipyretic	Opioid Analgesic (Schedule II Controlled Substance)
Production Volume	High (Hundreds of thousands of metric tons/year)	Low (Restricted by quotas)
Supplier Landscape	Fragmented, numerous global suppliers	Highly concentrated, few specialized licensed manufacturers
Key Manufacturing Regions	China, India, Europe, U.S.	Primarily U.S. and Europe
Regulatory Oversight	GMP, Pharmacopoeial Standards	GMP, Pharmacopoeial Standards, DEA Quotas, Strict Security
Supply Chain Complexity	Moderate	High
Price Volatility	Moderate (influenced by raw materials)	High (influenced by quotas, regulatory compliance, niche market)
Risk Profile	Raw material costs, geopolitical disruptions	Regulatory changes, diversion risk, limited supplier availability

Key Takeaways

The global supply for acetaminophen is characterized by high volume, broad geographic distribution, and a competitive manufacturing base. Sourcing typically focuses on cost optimization, quality assurance through GMP compliance, and managing raw material price volatility.

Conversely, the benzhydrocodone hydrochloride supply chain is tightly controlled and highly regulated due to its status as a Schedule II controlled substance. Manufacturing is limited to a few specialized entities, and production is constrained by strict government quotas. Strategic sourcing for this API necessitates a deep understanding of regulatory compliance, robust security protocols, and proactive engagement with regulatory bodies. Diversification strategies are significantly constrained by the controlled substance framework.

Frequently Asked Questions

1. What are the primary regulatory hurdles for sourcing acetaminophen API? Suppliers must demonstrate compliance with relevant pharmacopoeial standards (USP, EP, JP) and adhere to Good Manufacturing Practices (GMP). Regulatory bodies like the FDA and EMA conduct inspections, and manufacturers typically maintain Drug Master Files (DMFs) for review.

2. How does the DEA quota system impact benzhydrocodone hydrochloride availability? The DEA sets annual aggregate production quotas, limiting the total amount of benzhydrocodone hydrochloride that can be legally manufactured in the U.S. These quotas directly control supply and can lead to shortages if demand exceeds the allocated amount or if quotas are not adjusted in line with market needs.

3. Are there alternative suppliers emerging for benzhydrocodone hydrochloride? The emergence of new suppliers for Schedule II controlled substances is exceptionally rare and challenging due to the significant regulatory, security, and capital investment required to obtain DEA registration and establish compliant manufacturing operations.

4. What are the key factors influencing the price of acetaminophen? Acetaminophen pricing is primarily influenced by the cost of key chemical precursors (e.g., phenol, acetic anhydride), energy costs, labor expenses in manufacturing regions, and global supply-demand dynamics.

5. What due diligence is essential when selecting a supplier for benzhydrocodone hydrochloride? Beyond standard quality and GMP compliance, due diligence must include a thorough review of the supplier's DEA registration and history, security protocols, diversion control measures, record-keeping practices, and their track record with regulatory agencies. Audits must scrutinize their ability to operate within allocated quotas.

Citations

[1] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [DEA website] [2] International Narcotics Control Board. (n.d.). Role and Functions. Retrieved from [INCB website] [3] United States Pharmacopeia. (n.d.). Acetaminophen. Retrieved from [USP website] [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM website]